Synthetic vaccine and Immunogenic Fusion Proteins for pneumococcal infections (SJ-05-0036, SJ-10-0028, SJ-13-0032)
- Detailed Technology Description
- A vaccine comprising synthetically linked domains of choline binding protein A (CbpA) from Streptococcus pneumonia, and a new type of pneumococcus vaccine component in which a T-cell epitope (e.g. Pneulmolysin toxoid) is fused to immunogenic fragments of choline binding protein A (CbpA). This new fused vaccine component provides an easier, less costly and more efficient way to elicit an immune response to both the T-cell epitope and CbpA as compared to a mixture of separate antigens. The CbpA fragment used preferably comprises synthetically linked domains of CbpA. The CbpA peptide-pneumolysoid fusion construct is a viable broadly protective pneumococcal vaccine that potentially adds protection against other meningeal pathogens; and may be useful for treating or preventing infections such as sepsis, meningitis, and pneumonia. Also, SJ-13-0032, “YLN for Cardiac Indication,” involves using these vaccine components to avoid adverse cardiac events caused by pneumonia infections (This is co-owned with Univ. of Texas Health Science Center.)
- *Abstract
-
Granted Patents or Published Applications CbpA fragment (SJ-05-0036) U.S. Application published June 10, 2010 as US2010/0143394; CbpA peptide-pneumolysoid fusion construct (SJ-10-0028) published international application WO 2012/134975.
Related Scientific References
- Country/Region
- USA
For more information, please click Here
